LT3808775T - Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną - Google Patents

Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Info

Publication number
LT3808775T
LT3808775T LTEP20194168.9T LT20194168T LT3808775T LT 3808775 T LT3808775 T LT 3808775T LT 20194168 T LT20194168 T LT 20194168T LT 3808775 T LT3808775 T LT 3808775T
Authority
LT
Lithuania
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
LTEP20194168.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Elena BUROVA
Yajun Tang
Ka-Man Venus Lai
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3808775T publication Critical patent/LT3808775T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP20194168.9T 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną LT3808775T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
LT3808775T true LT3808775T (lt) 2024-07-10

Family

ID=55024286

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP20194168.9T LT3808775T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
LTEP15816631.4T LT3230320T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP15816631.4T LT3230320T (lt) 2014-12-09 2015-12-09 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną

Country Status (27)

Country Link
US (4) US9913461B2 (cg-RX-API-DMAC7.html)
EP (3) EP3230320B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018500896A (cg-RX-API-DMAC7.html)
KR (2) KR102457921B1 (cg-RX-API-DMAC7.html)
CN (2) CN113412818B (cg-RX-API-DMAC7.html)
AU (3) AU2015360667B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011982A2 (cg-RX-API-DMAC7.html)
CA (1) CA2968675C (cg-RX-API-DMAC7.html)
CY (1) CY1123723T1 (cg-RX-API-DMAC7.html)
DK (2) DK3808775T3 (cg-RX-API-DMAC7.html)
ES (2) ES2982515T3 (cg-RX-API-DMAC7.html)
FI (1) FI3808775T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20202034T1 (cg-RX-API-DMAC7.html)
HU (2) HUE067123T2 (cg-RX-API-DMAC7.html)
IL (3) IL282649B (cg-RX-API-DMAC7.html)
LT (2) LT3808775T (cg-RX-API-DMAC7.html)
MX (1) MX2017007636A (cg-RX-API-DMAC7.html)
NZ (2) NZ731954A (cg-RX-API-DMAC7.html)
PL (1) PL3808775T3 (cg-RX-API-DMAC7.html)
PT (2) PT3808775T (cg-RX-API-DMAC7.html)
RS (2) RS65664B1 (cg-RX-API-DMAC7.html)
RU (1) RU2711729C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202100792XA (cg-RX-API-DMAC7.html)
SI (2) SI3230320T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202400313T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016094481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703263B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE067123T2 (hu) * 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
AU2017228293B2 (en) 2016-02-29 2023-05-25 Regeneron Pharmaceuticals, Inc. Rodents having a humanized Tmprss gene
US10912287B2 (en) 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
CN109913493B (zh) 2017-12-12 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
FI3823443T3 (fi) 2018-07-16 2024-07-25 Regeneron Pharma Ditra-taudin jyrsijämallit ja niiden käyttö
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US20210380978A1 (en) * 2018-10-15 2021-12-09 The Brigham And Women`S Hospital, Inc. The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
US20240130340A1 (en) * 2021-02-19 2024-04-25 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
DE60322426D1 (cg-RX-API-DMAC7.html) * 2002-12-16 2008-09-04 Genentech Inc
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
ES2587344T3 (es) 2003-12-24 2016-10-24 Novo Nordisk A/S Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 and PD-1 in the treatment of renal cell carcinoma
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1997887B1 (en) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
BRPI0920679A2 (pt) 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
US20110314563A1 (en) * 2008-12-18 2011-12-22 Kingdon Craig R Antibody production
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
MX2012002427A (es) * 2009-08-28 2012-08-03 Vlst Corp Anticuerpos anticina que se unen a quimiocinas cc multiples.
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
WO2011060357A2 (en) 2009-11-16 2011-05-19 The Ohio State University Engineered xenogeneic cells for repair of biological tissue
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
RS57280B1 (sr) * 2009-12-21 2018-08-31 Regeneron Pharma Humanizovani fc gamma r miševi
EP2555778A4 (en) * 2010-04-06 2014-05-21 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION
KR102256316B1 (ko) * 2011-02-15 2021-05-28 리제너론 파마슈티칼스 인코포레이티드 인간화된 ｍ－ｃｓｆ 마우스
ES2741649T3 (es) 2011-10-28 2020-02-11 Regeneron Pharma Ratones con complejo mayor de histocompatibilidad modificado genéticamente
CA2853731C (en) 2011-10-28 2021-05-18 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
CN104039133B (zh) 2011-10-28 2018-05-04 瑞泽恩制药公司 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
PT3470432T (pt) * 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
CN108782459B (zh) 2012-09-07 2021-11-05 再生元制药公司 经遗传修饰的非人动物及其使用方法
IL299887B2 (en) 2012-11-05 2024-09-01 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
KR102714111B1 (ko) * 2013-02-20 2024-10-11 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
EP2958990B1 (en) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
HRP20181866T1 (hr) * 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR20200136508A (ko) * 2013-04-16 2020-12-07 리제너론 파마슈티칼스 인코포레이티드 랫트 게놈의 표적화된 변형
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
US20160122829A1 (en) 2013-06-06 2016-05-05 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms
KR102370419B1 (ko) 2013-09-23 2022-03-04 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
DK3129400T3 (da) 2014-04-08 2020-06-08 Regeneron Pharma Ikke-humane dyr med humaniserede Fc-gamma-receptorer
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
BR112016029650A2 (pt) * 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
PL3689140T3 (pl) 2014-11-24 2022-09-05 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
IL286403B2 (en) 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene
HUE067123T2 (hu) * 2014-12-09 2024-10-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
JP6997708B2 (ja) 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1

Also Published As

Publication number Publication date
US9913461B2 (en) 2018-03-13
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
ZA201703263B (en) 2023-02-22
EP3230320B1 (en) 2020-10-07
IL282649A (en) 2021-06-30
FI3808775T3 (fi) 2024-07-02
BR112017011982A2 (pt) 2018-01-16
US20180160663A1 (en) 2018-06-14
RU2017123754A3 (cg-RX-API-DMAC7.html) 2019-06-24
US20160157469A1 (en) 2016-06-09
JP7488861B2 (ja) 2024-05-22
JP2022184973A (ja) 2022-12-13
PL3808775T3 (pl) 2024-08-19
HRP20202034T1 (hr) 2021-02-19
US10881086B2 (en) 2021-01-05
RS65664B1 (sr) 2024-07-31
IL252695A0 (en) 2017-08-31
ES2841353T3 (es) 2021-07-08
IL282649B (en) 2022-07-01
CY1123723T1 (el) 2022-03-24
CN107257624A (zh) 2017-10-17
KR102457921B1 (ko) 2022-10-25
DK3808775T3 (da) 2024-07-01
SI3808775T1 (sl) 2024-08-30
WO2016094481A1 (en) 2016-06-16
IL252695B (en) 2020-07-30
EP3230320A1 (en) 2017-10-18
AU2021286369A1 (en) 2022-01-20
HUE067123T2 (hu) 2024-10-28
AU2021286369B2 (en) 2025-03-27
CA2968675C (en) 2023-10-17
CN113412818A (zh) 2021-09-21
HRP20240855T1 (hr) 2024-10-11
KR102316842B1 (ko) 2021-10-25
SG10202100792XA (en) 2021-03-30
AU2015360667B2 (en) 2021-09-23
EP4399969A3 (en) 2024-10-30
CN113412818B (zh) 2022-11-04
US20240389563A1 (en) 2024-11-28
IL275864B (en) 2021-05-31
JP2021003130A (ja) 2021-01-14
PT3230320T (pt) 2021-01-08
RU2711729C2 (ru) 2020-01-21
NZ770783A (en) 2024-11-29
JP2018500896A (ja) 2018-01-18
KR20210130251A (ko) 2021-10-29
AU2015360667A1 (en) 2017-06-08
EP3808775A1 (en) 2021-04-21
ES2982515T3 (es) 2024-10-16
SMT202100148T1 (it) 2021-05-07
SG11201703931QA (en) 2017-06-29
AU2025204751A1 (en) 2025-07-17
RS61218B1 (sr) 2021-01-29
MX2017007636A (es) 2018-03-28
LT3230320T (lt) 2021-01-11
NZ731954A (en) 2024-11-29
US20210105983A1 (en) 2021-04-15
DK3230320T3 (da) 2021-01-11
KR20170101910A (ko) 2017-09-06
RU2017123754A (ru) 2019-01-10
IL275864A (en) 2020-08-31
PT3808775T (pt) 2024-07-09
JP7145920B2 (ja) 2022-10-03
US12089575B2 (en) 2024-09-17
SI3230320T1 (sl) 2021-02-26
SMT202400313T1 (it) 2024-09-16
EP3808775B1 (en) 2024-04-17
HUE052606T2 (hu) 2021-05-28
EP4399969A2 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
IL282649A (en) Non-human animals with a humanized gene for differentiation cluster 274
IL286403A (en) Non-human animals having a humanized cluster of differentiation 47 gene
IL287519A (en) Non-human animals with a humanized programmed cell death gene 1
IL258841B (en) Non-human animals with human lymphocyte activation gene 3